Abstract
The injection of bulking agents into the urethral submucosa is designed to create artificial urethral cushions that can improve urethral coaptation and hence restore continence. Ideally, a urethral bulking agent should be non-immunogenic and biocompatible, leading to minimal inflammatory and fibrotic response. The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite. To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.
References
Dmochowski R, Appell R, Klimberg I, Mayer R (2002) Initial clinical results from coaptite injection for stress urinary incontinence comparative clinical study (Abstract). In: Proceedings of the International Continence Society (ICS), 32nd Annual Meeting, Heidelberg, Germany 28-30 Aug. 2002, pp184–185
Pickard R, Reaper J, Wyness L, Cody DJ, McClinton S, N’Dow J (2005) Periurethral injection therapy for urinary incontinence in women (Cochrane Review). In: The Cochrane Library, Issue 1, Update Software, Oxford
Palma PCR, Riccetto CLZ, Netto NR Jr (1996) Urethral pseudolipoma: a complication of periurethral lipo-injection for stress urinary incontinence in a woman. J Urol 155:646
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Palma, P.C.R., Riccetto, C.L.Z., Martins, M.H.T. et al. Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence. Int Urogynecol J 17, 670–671 (2006). https://doi.org/10.1007/s00192-005-0038-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00192-005-0038-x